secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001558370-23-018705
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma Q3 cash $16.2M; Phase 2 episodic migraine misses primary endpoint
--------------------------------------------------------------------------------

- Cash, equivalents and investments $16.2M as of Sep 30, 2023; expects to fund operations only into mid-December 2023.
- Phase 2 episodic migraine trial missed primary endpoint: mean MMD reduction 4.8 (150U) and 5.0 (195U) vs 4.2 placebo, not statistically significant.
- Secondary endpoints achieved statistical significance; company plans to advance to Phase 3 and request end-of-phase 2 meeting with FDA in 1H 2024.
- Chronic migraine Phase 2 enrollment on track to complete Q4 2023, topline data expected 2H 2024.
- Completed business combination and post-merger funding of ~$50M from new and existing investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000155837023018705/0001558370-23-018705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000155837023018705/aeon-20231113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer